Retraction notice to “Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells”
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).This article has been retracted at the request of the Editor in Chief. An investigation by Wayne State University identified a discrepancy between the data reported in Figures 1B, 2B and 3C and the original collected data. The investigation committee concluded that this undermined the scientific basis of the publication, that no credible replacement data were available, and advised that the publication should be retracted. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Bin Bao, Zhiwei Wang, Shadan Ali, Dejuan Kong, Yiwei Li, Aamir Ahmad, Sanjeev Banerjee, Asfar S. Azmi, Lucio Miele, Fazlul H. Sarkar Source Type: research
Editorial Board
(Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Source Type: research
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells
Molecular targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using low dose of the multikinase inhibitor sorafenib improves cyclophosphamide antitumor activity by inhibiting angiogenesis, metastasis and promoting tumor healing in MDA-MB231 xenografts and the 4T1-12B syngeneic breast cancer metastasis model. Mechanistic studies in MDA-MB231 cells revealed that alkylation upregulates inflammatory genes/proteins such as COX-2, IL8, CXCL2 and MMP1 in a MEK1/2-ERK1/2-dependent manner. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Alfeu Zanotto-Filho, Subapriya Rajamanickam, Eva Loranc, V. Pragathi Masamsetti, Aparna Gorthi, July Carolina Romero, Sonal Tonapi, Rosangela Mayer Gon çalves, Robert L. Reddick, Raymond Benavides, John Kuhn, Yidong Chen, Alexander J.R. Bishop Tags: Original Articles Source Type: research
A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma
Lung adenocarcinoma (LAC) is the most lethal cancer and the leading cause of cancer-related death worldwide. The identification of meaningful clusters of co-expressed genes or representative biomarkers may help improve the accuracy of LAC diagnoses. Public databases, such as the Gene Expression Omnibus (GEO), provide rich resources of valuable information for clinics, however, the integration of multiple microarray datasets from various platforms and institutes remained a challenge. To determine potential indicators of LAC, we performed genome-wide relative significance (GWRS), genome-wide global significance (GWGS) and su...
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Wan-Ting Liu, Yang Wang, Jing Zhang, Fei Ye, Xiao-Hui Huang, Bin Li, Qing-Yu He Tags: Original Articles Source Type: research
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma
In this study, we established a Survivin-targeted drug screening platform, a cell model HepG2-Sur5P-EGFP-Sur3U stably transfected with lentivirus carrying an EGFP expression cassette, in which the EGFP expression was regulated by the upstream Survivin promoter and downstream Survivin 3 ′-UTR. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Haisen Yin, Risheng Que, Chunying Liu, Weidan Ji, Bin Sun, Xuejing Lin, Qin Zhang, Xinying Zhao, Zhangxiao Peng, Xiaofeng Zhang, Haihua Qian, Lei Chen, Yonggang Yao, Changqing Su Tags: Original Articles Source Type: research
RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
In this study, we found shikonin activated RIP1 and RIP3 in glioma cells in vitro and in vivo, which was accompanied with glycolysis suppression. Further investigation revealed that shikonin-induced decreases of glucose-6-phosphate and pyruvate and downregulation of HK II and PKM2 were significantly prevented when RIP1 or RIP3 was pharmacologically inhibited or genetical ly knocked down with SiRNA. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Bin Lu, Zongqi Wang, Ye Ding, Xuanzhong Wang, Shan Lu, Chongcheng Wang, Chuan He, Meihua Piao, Guangfan Chi, Yinan Luo, Pengfei Ge Tags: Original Articles Source Type: research
Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells
Molecular targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using low dose of the multikinase inhibitor sorafenib improves cyclophosphamide antitumor activity by inhibiting angiogenesis, metastasis and promoting tumor healing in MDA-MB231 xenografts and the 4T1-12B syngeneic breast cancer metastasis model. Mechanistic studies in MDA-MB231 cells revealed that alkylation upregulates inflammatory genes/proteins such as COX-2, IL8, CXCL2 and MMP1 in a MEK1/2-ERK1/2-dependent manner. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Alfeu Zanotto-Filho, Subapriya Rajamanickam, Eva Loranc, Pragathi Masamsetti, Aparna Gorthi, July Carolina Romero, Sonal Tonapi, Rosangela Mayer Gon çalves, Robert L. Reddick, Raymond Benavides, John Kuhn, Yidong Chen, Alexander J.R. Bishop Tags: Original Articles Source Type: research
A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma
Lung adenocarcinoma (LAC) is the most lethal cancer and the leading cause of cancer-related death worldwide. The identification of meaningful clusters of co-expressed genes or representative biomarkers may help improve the accuracy of LAC diagnoses. Public databases, such as the Gene Expression Omnibus (GEO), provide rich resources of valuable information for clinics, however, the integration of multiple microarray datasets from various platforms and institutes remained a challenge. To determine potential indicators of LAC, we performed genome-wide relative significance (GWRS), genome-wide global significance (GWGS) and su...
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Wan-Ting Liu, Yang Wang, Jing Zhang, Fei Ye, Xiao-Hui Huang, Bin Li, Qing-Yu He Tags: Original Articles Source Type: research
Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma
In this study, we established a Survivin-targeted drug screening platform, a cell model HepG2-Sur5P-EGFP-Sur3U stably transfected with lentivirus carrying an EGFP expression cassette, in which the EGFP expression was regulated by the upstream Survivin promoter and downstream Survivin 3 ′-UTR. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Haisen Yin, Risheng Que, Chunying Liu, Weidan Ji, Bin Sun, Xuejing Lin, Qin Zhang, Xinying Zhao, Zhangxiao Peng, Xiaofeng Zhang, Haihua Qian, Lei Chen, Yonggang Yao, Changqing Su Tags: Original Articles Source Type: research
RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
In this study, we found shikonin activated RIP1 and RIP3 in glioma cells in vitro and in vivo, which was accompanied with glycolysis suppression. Further investigation revealed that shikonin-induced decreases of glucose-6-phosphate and pyruvate and downregulation of HK II and PKM2 were significantly prevented when RIP1 or RIP3 was pharmacologically inhibited or genetically knocked down with SiRNA. (Source: Cancer Letters)
Source: Cancer Letters - March 30, 2018 Category: Cancer & Oncology Authors: Bin Lu, Zongqi Wang, Ye Ding, Xuanzhong Wang, Shan Lu, Chongcheng Wang, Chuan He, Meihua Piao, Guangfan Chi, Yinan Luo, Pengfei Ge Tags: Original Articles Source Type: research
A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer
Tropomyosin-related kinase A (TrkA) plays important roles in tumor cell growth and survival signaling and contributes to chemo-resistance in pancreatic cancer. Therefore, we developed KK5101, a novel TrkA target inhibitor and assessed its anti-cancer effects and investigated underlying mechanism of action in pancreatic cancer. KK5101 was characterized to inhibit TrkA selectively and potently by protein binding assay. It effectively inhibited the growth and proliferation of pancreatic cancer cells. (Source: Cancer Letters)
Source: Cancer Letters - March 29, 2018 Category: Cancer & Oncology Authors: Zhenghuan Fang, Boreum Han, Kyung Hee Jung, Ju-Hyeon Lee, Ashraf Kareem El-Damasy, Changdev G. Gadhe, Soo Jung Kim, Hong Hua Yan, Jung Hee Park, Ji Eun Lee, Yeo Wool Kang, Ae Nim Pae, Gyochang Keum, Soon-Sun Hong Tags: Original Articles Source Type: research
Immunotherapy for pancreatic cancer: A long and hopeful journey
Multiple therapeutic strategies have been developed to treat pancreatic cancer. However, the outcomes of these approaches are disappointing. Due to deeper understandings of the pivotal roles of the immune system in pancreatic cancer tumorigenesis and progression, novel therapeutic strategies based on immune cells and the tumor microenvironment are being investigated. Some of these approaches, such as checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and BiTE antibodies, have achieved exciting outcomes in preclinical and clinical trials. (Source: Cancer Letters)
Source: Cancer Letters - March 29, 2018 Category: Cancer & Oncology Authors: Jian-wei Xu, Lei Wang, Yu-gang Cheng, Guang-yong Zhang, San-yuan Hu, Bin Zhou, Han-xiang Zhan Tags: Mini-review Source Type: research
Tetrandrine inhibits deregulated cell cycle in pancreatic cancer cells: Differential regulation of p21Cip1/Waf1, p27Kip1 and cyclin D1
In this study, we show for the first time that tetrandrine (TET) inhibits proliferation of the PaCa cells and inhibits PaCa tumor growth. TET inhibits cell cycle transition at G1/S boundary. TET increased levels of p21Cip1/Waf1 and p27Kip1, had no effect on the levels of CDK4/6 proteins and decreased the levels of cyclin D1 and pRb proteins. TET resulted in changes in mRNA levels of cyclin D1 and p21Cip1/Waf1 but had no effect on the mRNA of p27Kip1. (Source: Cancer Letters)
Source: Cancer Letters - March 29, 2018 Category: Cancer & Oncology Authors: Karnika Singh, Qin Dong, Prakash S. TimiriShanmugam, Sweaty Koul, Hari K. Koul Tags: Original Articles Source Type: research
Immunotherapy for pancreatic cancer: A long and hopeful journey
Multiple therapeutic strategies have been developed to treat pancreatic cancer. However, the outcomes of these approaches are disappointing. Due to deeper understandings of the pivotal roles of the immune system in pancreatic cancer tumorigenesis and progression, novel therapeutic strategies based on immune cells and the tumor microenvironment are being investigated. Some of these approaches, such as checkpoint inhibitors, chimeric antigen receptor T-cell therapy, and BiTE antibodies, have achieved exciting outcomes in preclinical and clinical trials. (Source: Cancer Letters)
Source: Cancer Letters - March 29, 2018 Category: Cancer & Oncology Authors: Jian-wei Xu, Lei Wang, Yu-gang Cheng, Guang-yong Zhang, San-yuan Hu, Bin Zhou, Han-xiang Zhan Tags: Mini-review Source Type: research
A Novel Tropomyosin-Related Kinase A Inhibitor, KK5101 to Treat Pancreatic Cancer
Tropomyosin-related kinase A (TrkA) plays important roles in tumor cell growth and survival signaling and contributes to chemo-resistance in pancreatic cancer. Therefore, we developed KK5101, a novel TrkA target inhibitor and assessed its anti-cancer effects and investigated underlying mechanism of action in pancreatic cancer. KK5101 was characterized to inhibit TrkA selectively and potently by protein binding assay. It effectively inhibited the growth and proliferation of pancreatic cancer cells. (Source: Cancer Letters)
Source: Cancer Letters - March 29, 2018 Category: Cancer & Oncology Authors: Zhenghuan Fang, Boreum Han, Kyung Hee Jung, Ju-Hyeon Lee, Ashraf Kareem El-Damasy, Changdev G. Gadhe, Soo Jung Kim, Hong Hua Yan, Jung Hee Park, Ji Eun Lee, Yeo Wool Kang, Ae Nim Pae, Gyochang Keum, Soon-Sun Hong Tags: Original Articles Source Type: research
